Clinical role of positron emission tomography in oncology

Lancet Oncology

Volumn 2, Issue 3, 2001, Pages 157-164

  Bomanji, J B ^a   Costa, D C ^a   Ell, P J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

COLORECTAL TUMOR; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HEAD AND NECK TUMOR; HUMAN; LUNG TUMOR; LYMPHOMA; MELANOMA; METHODOLOGY; NEOPLASM; REVIEW; SCINTISCANNING;

COLORECTAL NEOPLASMS; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; LYMPHOMA; MELANOMA; NEOPLASMS; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0035296491     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(00)00257-6     Document Type: Review

References (47)

1. Lienhard G.E., Slot J.W., James D.E., Mueckler M.M. How cells absorb glucose. Sci Am. 266:1992;34-39.
2. Berlangieri S.U., Scott A.M. Metabolic staging of lung cancer. N Engl J Med. 343:2000;290-292.
3. Dwamena B.A., Sonnad S.S., Angobaldo J.O., Wahl R.L. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s - meta-analytic comparison of PET and CT. Radiology. 213:1999;530-536.
4. Pieterman R.M., van Putten J.W.G., Meuzelaar J.J., et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med. 343:2000;254-261.
5. Gambhir S.S., Hoh C.G., Phelps M.E., et al. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small cell lung carcinoma. J Nucl Med. 37:1996;1428-1436.
6. Dietlein M., Weber K., Gandjour A., et al. Cost effectiveness of FDG-PET for the management of solitary pulmonary nodules: a decision analysis based on cost reimbursement in Germany. Eur J Nucl Med. 27:2000;1441-1456.
7. Lowe V.J., Naunheim K.S. Positron emission tomography in lung cancer. Ann Thorac Surg. 65:1998;1821-1829.
8. Lowe V.J., Fletcher J.W., Gobar L., et al. Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol. 16:1998;1075-1084.
9. Dewan N.A., Reeb S.D., Gupta N.C., et al. PET-FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions: a comparative risk-benefit analysis. Chest. 108:1995;441-446.
10. Lieberman D.A., Weiss D.G., Bond J.H., et al. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. N Engl J Med. 343:2000;162-168.
11. Kelsen D.P. Surrogate endpoints in assessment of new drugs in colorectal cancer. Lancet. 356:2000;353-354.
12. Buyse M., Thirion P., Carlson R.W., et al. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Lancet. 356:2000;373-378.
13. Abdel-Nabi H., Doerr R.J., Lamonica D.M., et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology. 206:1998;755-760.
14. Arulampalam T.H.A., Costa D.C., Loizidou M., et al. The role of positron emission tomography in the management of colorectal cancer. Br J Surg. 88:2001;1-14.
15. Delbeke D. Oncological applications of FDT PEG imaging: brain tumours, colorectal cancer, lymphoma and melanoma. J Nucl Med. 40:1999;591-603.
16. Schiepers C., Penninckx F., DeVadder N., et al. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol. 21:1995;517-522.
17. Ogunbiyi O., Flanagan F.L., Dehdashti F., et al. Detection of recurrent and metastatic colorectal cancer: comparison with positron emission tomography and computed tomography. Ann Surg Oncol. 4:1997;613-620.
18. Delbeke D., Vitola J.V., Sandler M.P., et al. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med. 38:1997;1196-1201.
19. Flanagan F.L., Dehdashti F., Ogunbiyi O.A., et al. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg. 227:1998;319-323.
20. 18F) fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg. 134:1999;503-511.
21. Haberkorn U., Strauss L.G., Dimitrakopoulou A., et al. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumours receiving radiotherapy. J Nucl Med. 32:1991;1485-1490.
22. Findlay M., Young H., Cunningham D., et al. Noninvasive monitoring of tumour metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumour response to fluorouracil. J Clin Oncol. 4:1996;700-708.
23. Vitola V.J., Delbeke D., Meranze S.G., et al. Positron emission tomography with F-18-fluorodeoxyglucose to evaluate the results of hepatic chemoembolization. Cancer. 78:1996;2216-2222.
24. Klose T., Leidl R., Buchmann I., et al. Primary staging of lymphomas: cost-effectiveness of FDG-PET versus computed tomography. Eur J Nucl Med. 27:2000;1457-1464.
25. Kostakoglu L, Leonard JP, Coleman M, et al. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) and gallium-67 scintigraphy in staging and follow-up of patients with lymphoma. Blood 1999; 94: 84a (abstr).
26. Kostakoglu L., Goldsmith S.J. F-18] fluorodeoxyglucose positron emission tomography in staging and follow-up of lympoma. Is it time to shift gears? Eur J Nucl Med. 27:2000;1564-1579.
27. Moog F., Bangerter M., Diederichs C.G., et al. Lymphoma: role of whole body 2-deoxy-2 [F-18] fluoro-D-glucose (FDG) PET in nodal staging. Radiology. 203:1997;795-800.
28. 18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Ann Oncol. 9:1998;1117-1122.
29. Bangerter M., Kotzerke J., Griesshammer M., et al. Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest. Acta Oncol. 38:1999;799-804.
30. Tyler D.S., Onaitis M., Kherani A., et al. Positron emission tomography scanning in malignant melanoma: clinical utility in patients with stage III disease. Cancer. 89:2000;1019-1025.
31. Eigtved A., Andersson A.P., Dahlstrom K., et al. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma. Eur J Nucl Med. 27:2000;70-75.
32. Holder W.D., White R.L., Zuger J.H., et al. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg. 227:1998;764-769.
33. 18] fluoro-2-deoxy-D-glucose. Cancer. 86:1999;114-118.
34. 18F-fluorodeoxyglucose dual-head positron emission tomography as a procedure for detecting simultaneous primary tumors in cases of head and neck cancer. Cancer. 86:1999;2370-2377.
35. 18F-FDG PET in oral cancer staging. Nucl Med Commun. 21:2000;379.
36. Adams S., Baum R.P., Stuckenson T., et al. Prospective comparison of F-18 FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med. 25:1998;1255-1260.
37. Benchaou M., Lehmann W., Slosman D.O., et al. The role of FDG-PET in the preoperative assessment of N-staging in head and neck cancer. Acta Otol Laryngol. 116:1996;332-335.
38. Wahl R.L., Zasadny K., Helvie M., et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol. 11:1993;2101-2111.
39. Greven K.M., Williams D.W., Keyes J.W., et al. Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation. Cancer. 74:1994;1355-1359.
40. Sugawara Y., Fischer S.J., Zasadny K.R., et al. Preclinical and clinical studies of bone marrow uptake of fluorine-18 fluorodeoxyglucose with or without granulocyte colony stimulating factor during chemotherapy. J Clin Oncol. 16:1998;173-180.
41. 18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: an overview of different analytical methods. Eur J Nucl Med. 27:2000;731-743.
42. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer. 13:1999;1773-1782.
43. Saleem A., Yap J., Osman S., et al. Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action. Lancet. 355:2000;2125-2131.
44. 18F]-FHPG. Eur J Nucl Med. 28:2001;40-49.
45. O'Doherty M.J., Marsden P.K. Being equipped for clinical PET. Lancet. 356:2000;1701-1703.
46. Therasse P., Arbuck S., Eisenhauer E., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 92:2000;205-216.
47. Padhani A.R., Husband J.E. Are current tumour response criteria relevant for the 21st century? Br J Radiol. 73:2000;1031-1033.